Contineum Therapeutics (CTNM) Share-based Compensation (2023 - 2026)

Contineum Therapeutics' Share-based Compensation history runs 4 years deep, the most recent figure standing at $3.8 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 1338.2% year-over-year to $3.8 million; the TTM figure through Jun 2026 stood at $10.4 million (up 41.12% YoY), while the FY2025 annual figure was $10.0 million, down 51.51% from the prior year.
• Share-based Compensation for Q2 2026 stood at $3.8 million, roughly flat from $3.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $23.1 million in Q3 2025, with the low at $5000.0 in Q1 2023.
• The 4-year median for Share-based Compensation is $2.4 million (2024), against an average of $3.9 million.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 183900.0% in 2024, then slumped 72.08% in 2025.
• Contineum Therapeutics' Share-based Compensation stood at $759000.0 in 2023, then surged by 196.57% to $2.3 million in 2024, then climbed by 10.26% to $2.5 million in 2025, then jumped by 54.71% to $3.8 million in 2026.
• Business Quant data shows CTNM's Share-based Compensation at $3.8 million in Q2 2026, $3.8 million in Q1 2026, and $2.5 million in Q4 2025.